Showing 1201-1210 of 5659 results for "".
Empathy and Transactional Medicine: Improving Patient and Physician Outcomes
https://practicaldermatology.com/topics/skin-cancer-photoprotection/transactional-medicine-improving-patient-and-physician-outcomes/20316/For each individual patient, the patient-physician interaction is unique and requires vulnerability, exposure, and discomfort.Digital Innovation to the Rescue: The Future of Electronic Prior Authorization in Dermatology
https://practicaldermatology.com/topics/practice-management/digital-innovation-to-the-rescue-the-future-of-electronic-prior-authorization-in-dermatology/20467/Adopting new technology to reduce paperwork, costs, and burnout as well as improve patient care.Hyperpigmentation Treatment Pearls and More
https://practicaldermatology.com/conferences/cosmetic-surgery-forum-2022/hyperpigmentation-treatment-pearls-and-more/20161/Corey Hartman, MD shares his approach to treating periorbital hyperpigmentation in darker skin types, including using fillers to replace volume, give lift, and replace loss of bony structures and fat pads. Dr. Hartman also discusses the benefits of Cynosure’s PicoSure device to correct hyperpigmentaDermWireTV: Incyte's Opzelura, BMS Patient Week, Science of Skincare Summit
https://practicaldermatology.com/topics/psoriasis/dermwiretv-incytes-opzelura-bms-patient-week-science-of-skincare-summit/20003/Incyte’s Opzelura is the first topical JAK inhibitor approved in the US. Lawrence Eichenfield, MD weighs in on the cream formulation of ruxolitinib for treatment of mild-to-moderate atopic dermatitis in non-immunocompromised patients 12 years of age and older. Bristol Myers Squibb's seventh Global PDermWireTV: LEO Science & Tech Hub, Allergan/SkinBetter DREAM Initiative, San Diego Dermatology Symposium
https://practicaldermatology.com/topics/skin-cancer-photoprotection/dermwiretv-leo-pharma-science-tech-hub-allerganskinbetter-dream-initiative-san-diego-dermatology-symposium/19856/Innovation Endeavors and the LEO Science & Tech Hub kick off a Deep Life Challenge program. Allergan Aesthetics, an AbbVie company, and Skinbetter Science launch a new long-term, educational initiative: The DREAM (Driving Racial Equity in Aesthetic Medicine) Initiative. The San Diego DermatologyMedical Derm at Summer AAD; Novel Drugs, Acne at Derm 2018
https://practicaldermatology.com/topics/skin-cancer-photoprotection/dermwiretv-medical-derm-at-summer-aad-novel-drugs-acne-at-derm-2018/18244/The Summer meeting of the American Academy of Dermatology (AAD) gathers members for updates on medical and aesthetic advancements. This year, topics included advanced therapeutics, skin cancer, and skin of color. DERM 2018 provides an opportunity for nurse practitioners and physician assistants in dOrtho Dermatologics NDA, J&J Innovation, Consumer Credit Insights
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-ortho-dermatologics-nda-j-j-innovation-consumer-credit-insights/18395/Two-thirds of prospective patients say they would be more likely to book a procedure if they were aware of financing options. More than three-quarters of prospective patients are unaware of financing options, according to a recent survey by Zalea. In conjunction with Johnson & Johnson Consumer,DermWireTV: Arcutis Takes PASI HD; Galderma at Camp Wonder; Amgen Challenge; LaRoche-Posay Pride
https://practicaldermatology.com/topics/psoriasis/dermwiretv-arcutis-takes-pasi-hd-galderma-at-camp-wonder-amgen-challenge-laroche-posay-pride/19996/The PASI high discrimination or PASI-HD tool was developed by Arcutis Biotherapeutics in collaboration with a panel of psoriasis research experts. Led by Amgen, in partnership with the International Federation of Psoriasis Associations, the Understanding Psoriatic Disease Leveraging Insights for TreAltreno's Approval, Psoriasis Insights
https://practicaldermatology.com/topics/psoriasis/dermwire-tv-altreno-s-approval-psoriasis-insights--nxhineya/18236/Ortho Dermatologics' Altreno lotion is now approved for the topical treatment of acne vulgaris in patients ages 9 and up. Altreno, containing tretinoin 0.05%, will be available during the fourth quarter of this year. The FDA has accepted Ortho Dermatologics' resubmitted New Drug Application for DuobDermWireTV: Candela + Merz Aesthetics Partnership, COVID-19 Vaccines & Fillers, Almirall's Klisyri, MetSyn & PsO
https://practicaldermatology.com/topics/skin-cancer-photoprotection/dermwiretv-candela-merz-aesthetics-partnership-covid-19-vaccines-and-fillers-almiralls-klisyri-metsyn-and-pso/19893/Klisyri® (tirbanibulin) ointment 1% from Almirall will be available for treatment of AKs by the end of this quarter; Ayman Grada, MD discusses. Are patients who have received dermal filler injections at risk for developing reactions to the COVID-19 vaccine? Joel L. Cohen, MD and Doris Day, MD weigh